Superluminal Raises $60 Million to Move a Biased MC4R Agonist into Phase I
Superluminal Medicines closed an oversubscribed $60 million Series B led by BVF Partners, with new participation from Deep Track Capital and Perceptive Advisors and follow-on support from RA Capital, Insight Partners, NVIDIA, Catalio, Eli…
